參考文獻(xiàn)/References:
[1] WU Y,ZHANG G,WANG N,et al.Risk factors of renal involvement based on different manifestations in patients with ankylosing spondylitis[J].Kidney Blood Press Res,2018,43(2):367-377.
[2] 吳珊珊,段振華.強(qiáng)直性脊柱炎流行病學(xué)研究進(jìn)展[J].安徽醫(yī)科大學(xué)學(xué)報(bào),2013,48(8):988-992.
[3] NURULLAH A,YARKAN H,GÖKÇE K,et al.Ankylosing spondylitis:HLA-B*27-positive versus HLA-B*27-negative disease[J].Curr Rheumatol Rep,2017,19(5):322-328.
[4] BREWERTON D A.HLA-B27 and the inheritance of susceptibility to rheumatic disease[J].Arthritis Rheum,2010,19(4):656-668.
[5] AKASSOU A,YACOUBI H,JAMIL A,et al.Prevalence of HLA-B27 in Moroccan healthy subjects and patients with ankylosing spondylitis and mapping construction of several factors influencing AS diagnosis by using multiple correspondence analysis[J].Rheumatol Int,2015,35(11):1889-1894.
[6] LIN H,GONG Y Z.Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis:a meta-analysis[J].Rheumatol Int,2017,37(8):1267-1280.
[7] KHAN M A,MATHIEU A,SORRENTINO R A.The pathogenetic role of HLA-B27 and its subtypes[J].Autoimmun Rev,2007,6(3):183-189.
[8] LIU Y,JIANG L,CAI Q,et al.Predominant association of HLA-B*2704 with ankylosing spondylitis in Chinese Han patients[J].Tissue Antigens,2010,75(1):61-64.
[9] TAUROG J D,DORRIS M L,SATUMTIRA N,et al. Spondylarthritis in HLA–B27/human β2-microglobulin–transgenic rats is not prevented by lack of CD8[J].Arthritis Rheum,2009,60(7):1977-1984.
[10] LORIES R J.Animal models of spondyloarthritis[J].Curr Opin Rheumatol,2006,18(4):342-346.
[11] ZHANG L,ZHANG Y J,CHEN J,et al.The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis:A systematic review[J].Microb Pathog,2018,117:49-54.
[12] KOLLNBERGER S,BIRD L,SUN M Y,et al.Cell-surface expression and immune receptor recognition of HLA-B27 homodimers[J].Arthritis Rheum,2002,46(11):2972-2982.
[13] BOWNESS P,RIDLEY A,SHAW J,et al.Th17 cells expressing KIR3DL2+and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis[J].J Immunol,2011,186(4):2672-2680.
[14] ZHAI J,RONG J,LI Q,et al.Immunogenetic study in Chinese population with ankylosing spondylitis:are there specific genes recently disclosed?[J/OL].Clin Dev Immunol,2013[2018-12-15].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562651.
[15] International Genetics of Ankylosing Spondylitis Consortium.Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci[J].Nat Genet,2013,45(7):730-738.
[16] GARCÍA-MEDEL N,SANZ-BRAVO A,VAN NGUYEN D,et al.Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA-B27 in vivo[J].Mol Cell Proteomics,2012,11(11):1416-1429.
中醫(yī)正骨2019年4月第31卷第4期 J Trad Chin Orthop Trauma,2019,Vol.31,No.4(總291)
(總292)中醫(yī)正骨2019年4月第31卷第4期 J Trad Chin Orthop Trauma,2019,Vol.31,No.4
[17] Wellcome Trust Case Control Consortium,Australo-Anglo-American Spondylitis Consortium,BURTON P R,et al.Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants[J].Nat Genet,2007,39(11):1329-1337.
[18] MAKSYMOWYCH W P,INMAN R D,GLADMAN D D,et al.Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis[J].Arthritis Rheum,2009,60(5):1317-1323.
[19] EVANS D M,SPENCER C C,POINTON J J,et al.Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility[J].Nat Genet,2011,43(8):761-767.
[20] 曲哲,錢邦平,邱勇,等.ERAP1基因單核苷酸多態(tài)性與中國(guó)漢族人群強(qiáng)直性脊柱炎的易感性關(guān)聯(lián)分析[J].中國(guó)脊柱脊髓雜志,2015,25(9):832-836.
[21] ETHWA H,BOWNESS P.The interleukin(IL)-23/IL-17 axis in ankylosing spondylitis:new advances and potentials for treatment[J].Clin Exp Immunol,2016,183(1):30-36.
[22] BABAIE F,HASANKHANI M,MOHAMMADI H A,et al.The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis:New insights and updates[J].Immunol Lett,2018,196:52-62.
[23] DANOY P,PRYCE K,HADLER J,et al.Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease[J].PLoS Genet,2010,6(12):e1001195.
[24] DI MEGLIO P,DI CESARE A,LAGGNER U,et al.The IL23R R381Q gene variant protects against Immune-Mediated diseases by impairing IL-23-Induced Th17 effector response in humans[J].PLoS One,2011,6(2):e17160.
[25] DAVIDSON S I,WU X,LIU Y,et al.Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population[J].Arthritis Rheum,2009,60(11):3263-3268.
[26] DAVIDSON S I,JIANG L,CORTES A,et al.High-Throughput sequencing of IL23R reveals a Low-Frequency,nonsynonymous Single-Nucleotide polymorphism that is associated with ankylosing spondylitis in a Han Chinese population[J].Arthritis Rheum,2013,65(7):1747-1752.
[27] CHEN C,ZHANG X E,WANG Y.Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population[J].Clinical Immunology,2010,136(3):442-446.
[28] BROWN M A.Breakthroughs in genetic studies of ankylosing spondylitis[J].Rheumatology,2008,47(2):132-137.
[29] LUBRANO E,PERROTTA F M.Secukinumab for ankylosing spondylitis and psoriatic arthritis[J].Ther Clin Risk Manag,2016,12:1587-1592.
[30] 蔡慧顏,鐘華.強(qiáng)直性脊柱炎患者外周血TNF-α、IL-17、IL-23的表達(dá)[J].現(xiàn)代診斷與治療,2016,27(18):3340-3342.
[31] JIAO Y L,MA C Y,WANG L C,et al.Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis:Possible association with susceptibility to the disease[J].J Clin Immunol,2008,28(4):343-349.
[32] DÍAZ-PEÑA R,VIDAL-CASTIEIRA R J,ALONSO-ARIAS R,et al.Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis[J].Arthritis Rheum,2010,62(4):1000-1006.
[33] Australo-Anglo-American Spondyloarthritis Consortium,REVEILLE J D,SIMS A M,et al.Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci[J].Nat Genet,2010,42(2):123-127.
相似文獻(xiàn)/References:
[1]閻曉霞,任之強(qiáng),仝允輝,等.布魯氏菌性脊柱炎3例[J].中醫(yī)正骨,2015,27(06):64.
[2]趙偉光,劉振武,劉利,等.強(qiáng)直性脊柱炎合并右側(cè)股骨頭和股骨頸骨溶解癥1例[J].中醫(yī)正骨,2015,27(01):75.
[3]黃建武,黃建華,黃影.腫瘤壞死因子-α在強(qiáng)直性脊柱炎活動(dòng)期患者中的表達(dá)[J].中醫(yī)正骨,2013,25(11):22.
[4]張董喆,孔超,張建福.針刺夾脊穴結(jié)合督灸治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2014,26(07):58.
[5]吳建國(guó).強(qiáng)直性脊柱炎并發(fā)脊柱骨折的影像學(xué)表現(xiàn)[J].中醫(yī)正骨,2013,25(06):31.
[6]謝國(guó)華,薛峰,楊建平,等.強(qiáng)直性脊柱炎脊柱應(yīng)力性骨折的診斷[J].中醫(yī)正骨,2012,24(12):72.
[7]張萬(wàn)義,張永紅,王笑青.雙醋瑞因膠囊聯(lián)合柳氮磺胺吡啶腸溶片與右旋布洛芬膠囊治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2012,24(06):26.
ZHANG Wan-yi*,ZHANG Yong-hong,WANG Xiao-qing.*.Study on the curative effects of diacerein capsules combined with sulfasalazine enteric-coated tablets and dextral ibuprofen capsules in the treatment of ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(04):26.
[8]黃建華,黃建武,陳金春,等.早期強(qiáng)直性脊柱炎血管內(nèi)皮生長(zhǎng)因子、C反應(yīng)蛋白
表達(dá)水平的臨床研究[J].中醫(yī)正骨,2012,24(02):9.
HUANG Jian-hua*,HUANG Jian-wu,CHEN Jin-chun,et al.Clinical research on the expression of VEGF、CRP in early ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(04):9.
[9]王笑青,張永紅,王玉麗,等.常規(guī)藥物口服配合中藥離子導(dǎo)入治療強(qiáng)直性脊柱炎肌腱附著點(diǎn)炎[J].中醫(yī)正骨,2011,23(10):18.
WANG Xiao-qing*,ZHANG Yong-hong,WANG Yu-li,et al.A study on the curative effects of oral conventional drugs combined with traditional Chinese medicine iontophoresis on ankylosing spondylitis tendon enthesitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(04):18.
[10]劉紅軍.單節(jié)段楔形截骨結(jié)合椎弓根A-F系統(tǒng)內(nèi)固定
治療強(qiáng)直性脊柱炎脊柱后凸畸形[J].中醫(yī)正骨,2011,23(09):65.
[11]戴霞華,李寅潔.指導(dǎo)性功能鍛煉在兒童強(qiáng)直性脊柱炎護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(10):78.
[12]張夢(mèng)雨,鮑鐵周,田江波.督脈隔姜灸聯(lián)合柳氮磺吡啶腸溶片口服及
功能鍛煉治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2015,27(09):44.
[13]赫軍,諸葛天諭,李冬冬,等.中藥內(nèi)服聯(lián)合針刺與埋針法治療幼年強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(01):41.
[14]赫軍,諸葛天諭,李冬冬,等.四聯(lián)療法治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(06):50.
[15]張遂連,袁星星.自我管理在強(qiáng)直性脊柱炎患者門診護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2017,29(03):79.
[16]李現(xiàn)林,薛華珍,陳星,等.口服通痹舒筋丸治療強(qiáng)直性脊柱炎寒濕痹阻證[J].中醫(yī)正骨,2017,29(05):31.
[17]龔家川.影響強(qiáng)直性脊柱炎患者髖關(guān)節(jié)受累的危險(xiǎn)因素分析[J].中醫(yī)正骨,2017,29(06):25.
GONG Jiachuan.Analysis of risk factors for affection of hip joint in patients with ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):25.
[18]黃小龍,全仁夫,胡華輝,等.HLA-B2704基因型強(qiáng)直性脊柱炎患者來(lái)源的人誘導(dǎo)多能干細(xì)胞體系的建立[J].中醫(yī)正骨,2017,29(12):11.
HUANG Xiaolong,QUAN Renfu,HU Huahui,et al.Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):11.
[19]李洛宜,張依山,王笑青,等.系列化視頻在強(qiáng)直性脊柱炎健康教育中的應(yīng)用[J].中醫(yī)正骨,2018,30(03):78.
[20]楊愛娟,徐保平,王曉濤.新風(fēng)膠囊治療強(qiáng)直性脊柱炎臨床療效的系統(tǒng)評(píng)價(jià)[J].中醫(yī)正骨,2020,32(07):12.
YANG Aijuan,XU Baoping,WANG Xiaotao.Clinical efficacy of Xinfeng(新風(fēng))capsule for treatment of ankylosing spondylitis:a systematic review[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(04):12.